GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (OTCPK:OXBDF) » Definitions » PB Ratio

Oxford BioMedica (Oxford BioMedica) PB Ratio : 4.55 (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Oxford BioMedica PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-26), Oxford BioMedica's share price is $4.4006. Oxford BioMedica's Book Value per Share for the quarter that ended in Dec. 2023 was $0.97. Hence, Oxford BioMedica's PB Ratio of today is 4.55.

The historical rank and industry rank for Oxford BioMedica's PB Ratio or its related term are showing as below:

OXBDF' s PB Ratio Range Over the Past 10 Years
Min: 0.79   Med: 8.32   Max: 101.39
Current: 4.28

During the past 13 years, Oxford BioMedica's highest PB Ratio was 101.39. The lowest was 0.79. And the median was 8.32.

OXBDF's PB Ratio is ranked worse than
71.57% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs OXBDF: 4.28

During the past 12 months, Oxford BioMedica's average Book Value Per Share Growth Rate was -64.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -17.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 14.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 24.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Oxford BioMedica was 140.10% per year. The lowest was -39.60% per year. And the median was -13.40% per year.

Back to Basics: PB Ratio


Oxford BioMedica PB Ratio Historical Data

The historical data trend for Oxford BioMedica's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica PB Ratio Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.86 7.72 5.77 2.02 2.78

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.77 1.92 2.02 2.39 2.78

Competitive Comparison of Oxford BioMedica's PB Ratio

For the Biotechnology subindustry, Oxford BioMedica's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's PB Ratio distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's PB Ratio falls into.



Oxford BioMedica PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Oxford BioMedica's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=4.4006/0.968
=4.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Oxford BioMedica  (OTCPK:OXBDF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Oxford BioMedica PB Ratio Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica (Oxford BioMedica) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.